Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells

Biochemical and Biophysical Research Communications

Volumn 419, Issue 3, 2012, Pages 529-536

  Yamazaki, Hiroto ^a   Naito, Motohiko ^a   Ghani, Farhana Ishrat ^a   Dang, Nam H ^b   Iwata, Satoshi ^a   Morimoto, Chikao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cancer stem cells; CD24; CD26; Malignant mesothelioma

Indexed keywords

CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER INVASION; CANCER STEM CELL; CELL PROLIFERATION; IN VITRO STUDY; MESOTHELIOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR GENE;

ANTIGENS, CD24; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; CELL LINE, TUMOR; DAUNORUBICIN; DIPEPTIDYL PEPTIDASE 4; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MESOTHELIOMA; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84858277698     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.054     Document Type: Article

References (27)

1. Ismaril-Khan R., Robinson L.A., Williams C.C.J., et al. Malignant pleural mesothelioma, a comprehensive review. Cancer Control 2006, 13:255-263.
2. Corson J.M. Pathology of mesothelioma. Thrac. Surg. Clin. 2004, 14:447-460.
3. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003, 21:2636-2644.
4. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
5. Wang J.C.Y., Dick J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005, 15:494-501.
6. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 2010, 120:41-50.
7. Kayo H., Yamazaki H., Nishida H., et al. Stem cell properties and the side population cell as a target for interferon-α in adult T-cell leukemia/lymphoma. Biochem. Biophys. Res. Commun. 2007, 364:808-814.
8. Nishida H., Yamazaki H., Yamada T., et al. CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells. Biochem. Biophys. Res. Commun. 2009, 382:57-62.
9. Yamazaki H., Nishida H., Iwata S., et al. CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells. Biochem. Biophys. Res. Commun. 2009, 383:172-177.
10. Yamazaki H., Xu C.W., Naito M., et al. Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia. Biochem. Biophys. Res. Commun. 2011, 409:14-21.
11. Li C., Heidt D.G., Dalerba P. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
12. + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2672-2680.
13. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Rev. Cancer 2008, 8:755-768.
14. + cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6:603-615.
15. Inamoto T., Yamada T., Ohnuma K., et al. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res. 2007, 13:4191-4200.
16. Ghani F.I., Yamazaki H., Iwata S., et al. Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem. Biophys. Res. Commun. 2011, 404:735-742.
17. T. Benatar, W. Yang, Y. Amemiya, et al., IGFBP-7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res. Treat, doi: 10.1007/s10549-011-1816-4.
18. Mehta H.H., Gao Q., Galet C., et al. IGFBP3 is a metastasis suppressor gene in prostate cancer. Cancer Res. 2011, 71:5154-5163.
19. Wajapeyee N., Serra R.W., Zhu X., et al. Oncogeneic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
20. Amemiya Y., Yang W., Benatar T., et al. Insulin like growth factor biding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Res. Treat. 2011, 126:373-384.
21. Ramos-Nino M.E., Timblin C.R., Mossman B.T. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res. 2002, 62:6065-6069.
22. Cortes-Dericks L., Carboni G.L., Schmid R.A., et al. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed. Int. J. Oncol. 2010, 37:437-444.
23. Morimoto C., Schlossman S.F. The structure and function of CD26 in the T-cell immune response. Immunol. Rev. 1998, 161:55-70.
24. Yamaguchi U., Nakayama R., Honda K., et al. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J. Clin. Oncol. 2008, 26:4100-4108.
25. Ohnuma K., Ishii T., Iwata S., et al. G1-S cell cycle arrest provoked in human T cells by antibody to CD26. Immunology 2002, 107:325-333.
26. Ho L., Aytac U., Stephens L.C., et al. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin. Cancer Res. 2001, 7:2031-2040.
27. Heesch S., Schlee C., Neumann M., et al. BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. Leukemia 2010, 24:1429-1436.